Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ECOR vs PACB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ECOR Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 4–4 Matrix Metrics)

ECOR Overall Winner 6-Pillar Tally: ECOR 4 – 1 PACB (1 Tie) Matrix Metrics: ECOR 4 – 4 PACB

As of Nov 19, 2026, electroCore, Inc. (ECOR) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ECOR carries a Unified Composite Score of 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin), whereas PACB carries 60.0/100 (BUY) at $1.76 (N/M Forward P/E, -333.0% operating margin).

  • Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. ECOR 56.8/100 HOLD), ECOR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-33.1% vs. -333.0% operating margin) and revenue trajectory (+11.5% vs. +5.5% YoY).
  • Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile PACB is in a Breakdown options structure phase (RSI 38.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ECOR vs PACB
ECOR NASDAQ Head-to-Head Winner
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.85
-6.19% 1D
Market Cap $47.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.52β · 155% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 68.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.5%), weak momentum, RSI 32
RSI-14: 31.5 · SMA20: $6.90 · SMA50: $8.67
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.76
-3.83% 1D
Market Cap $571.4M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.27β · 103% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 59.0 Fund 52.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.5 · SMA20: $2.25 · SMA50: $2.05

6-Pillar Scorecard Institutional Category Breakdown (ECOR 4 – 1 PACB)

Columns: Metric · ECOR · PACB
1. Valuation Multiples ECOR
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.4x 7.6x
2. Growth & Scale PACB
Revenue Growth (YoY) +11.5% +5.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $38M $161M
Market Cap $47.7M $571.4M
3. Profitability & Quality ECOR
Gross Margin 87.7% 27.7%
Operating Margin -33.1% -333.0%
Net Profit Margin -33.5% -81.3%
Return on Equity (ROE) -478.7% -929.3%
4. Balance Sheet & Cash Flow ECOR
Cash Generation (TTM) -$6.9M -$150M
Cash Flow Margin -18.1% -93.2%
Net Cash / Leverage $4.6M Net Debt $649M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ECOR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 191.0% (97th %ile)
Put/Call OI Skew N/A 0.02x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ECOR (4) vs PACB (4)
Institutional Metric ECOR PACB Criterion Row Edge
Market Capitalization
Scale
$47.7M $571.4M Larger Scale PACB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+11.5% +5.5% Higher Growth ECOR
Operating Margin (TTM)
Profitability
-33.1% -333.0% Higher Margin ECOR
Net Profit Margin
Profitability
-33.5% -81.3% Higher Margin ECOR
Return on Equity (ROE)
Capital Efficiency
-478.7% -929.3% Higher ROE ECOR
52-Week Range Position
Momentum
6% ($4–$13) 29% ($1–$3) Stronger Trend PACB
Beta / 30D Volatility
Risk Regime
1.52β · 155% Vol 2.27β · 103% Vol Lower Realized Risk PACB
Unified Institutional Score
Composite Signal
56.8 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite PACB
Trailing 12M Revenue (USD)
Operating Scale
$38M $161M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% 27.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · 7.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.9M ($4.6M Net Debt) -$150M ($649M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACB +16.25 pp
ECOR: -34.01% · PACB: -17.76%
3M Horizon PACB +84.27 pp
ECOR: -53.9% · PACB: +30.37%
6M Horizon PACB +59.83 pp
ECOR: -19.03% · PACB: +40.8%
1Y Horizon PACB +10.63 pp
ECOR: -3.96% · PACB: +6.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ECOR Revenue PACB Revenue ECOR Op. Margin PACB Op. Margin Margin Leader
FY2018 $0M $80M -5494.1% -128.4% PACB
FY2019 $0M $90M -1928.2% -110.6% PACB
FY2020 $0M $80M -707.9% -132.3% PACB
FY2021 $10M $130M -367.7% -161.2% PACB
FY2022 $10M $130M -266.2% -239.4% PACB
FY2023 $20M $200M -120.2% -166.8% ECOR
FY2024 $30M $150M -48.3% -308.0% ECOR
FY2025 $30M $160M -41.1% -346.2% ECOR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
15d in phase · OBV DISTRIBUTION
Current IV 191.0%
IV Percentile 97th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $47.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $571.4M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ECOR vs PACB Key Questions & Quantitative Answers

As of Nov 19, 2026, electroCore, Inc. (ECOR) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ECOR carries a Unified Composite Score of 56.8/100 (HOLD) at $4.85 (N/M Forward P/E, -33.1% operating margin), whereas PACB carries 60.0/100 (BUY) at $1.76 (N/M Forward P/E, -333.0% operating margin). Composite vs. Pillar Nuance: While PACB currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. ECOR 56.8/100 HOLD), ECOR captures the overall institutional head-to-head verdict (4–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-33.1% vs. -333.0% operating margin) and revenue trajectory (+11.5% vs. +5.5% YoY). Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile PACB is in a Breakdown options structure phase (RSI 38.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PACB leads the Growth & Scale pillar: ECOR posts +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin), compared with PACB at +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ECOR cumulative revenue shifted +200.0% while PACB shifted +100.0%. In operating R&D and SG&A reinvestment, ECOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PACB.

ECOR screens cheaper on headline valuation multiples. ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin), whereas PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.6x EV/Revenue (-93.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECOR (-478.7% ROE) versus PACB (-929.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk). By comparison, PACB carries 191.0% implied volatility (97th %ile, Extreme (>80th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.27β · 103% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.